Target genes and cellular regulators of the Myc transcription complex

Critical Reviews in Eukaryotic Gene Expression

Volumn 8, Issue 3-4, 1998, Pages 277-296

  Peters, Mette A ^a   Taparowsky, Elizabeth J ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Myc; Oncogenes; Transcription; Transformation

Indexed keywords

CANCER; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; GENE CONTROL; GENE TARGETING; HUMAN; ONCOGENE MYC; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0032471102     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v8.i3-4.30     Document Type: Review

References (225)

1. Abrams HD, Rohrschneider LR, Eisenman RN (1982): Nuclear location of the putative transforming protein of avian myelocytomatosis virus. Cell 29:427-439.
2. Akeson R, Bernards R (1990): N-Myc down regulates neural cell adhesion molecule expression in rat neuroblastoma. Mol Cell Biol 10:2012-2016.
3. Albert T, Urlbauer B, Kohlhuber F, Hammersen B, Eick D (1994): Ongoing mutations in the N-terminal domain of c-Myc affect transactivation in Burkitt's lymphoma cell lines. Oncogene 9:759-763.
4. Alexandrov I, Shlyakhova L, Vartanian A, Zajac-Kaye M, Alexandrova N (1997): c-Raf kinase binds to the N-terminal domain of c-Myc. FEBS Lett 414:465-470.
5. Alexandrova N, Niklinski J, Bliskovsky V, Otterson GA, Blake M, Kaye FJ, Zajac-Kaye M (1995): The N-terminal domain of c-Myc associates with α-tubulin and microtubules in vivo and in vitro. Mol Cell Biol 15: 5188-5195.
6. Amati B, Dalton S, Brooks MW, Littlewood TD, Evan GI, Land H (1992): Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max. Nature 359:423-426.
7. Amati B, Littlewood TD, Evan GI, Land H (1993a): The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 12: 5083-5087.
8. Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H (1993b): Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 72:233-245.
9. Askew DS, Ashmun RA, Simmons BC, Cleveland JL (1991): Constitutive c-Myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922.
10. Austen M, Cerni C, Henriksson M, Hilfenhaus S, Lüscher-Firzlaff JM, Menkel A, Seelos C, Sommer A, Lüscher B (1997): Regulation of cell growth by the Myc-Max-Mad network: role of Mad proteins and YY1. Current Topics in Micro Immun 224:123-130.
11. Austen M, Cerni C, Lüscher-Firzlaff JM, Lüscher B (1998): YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc. Oncogene, in press.
12. Ayer DE, Kretzner L, Eisenman RN (1993): Mad: A heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 72:211-222.
13. Ayer DE, Lawrence QA, Eisenman RN (1995): Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776.
14. Bao J, Zervos AS (1996): Isolation and characterization of Nmil, a novel partner of Myc proteins. Oncogene 12:2171-2176.
15. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV (1992): Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol 12:3130-3137.
16. Barrett JF, Lewis BC, Hoang AT, Alvarez RJ Jr, Dang CV (1995): Cyclin A links c-Myc to adhesion-independent cell proliferation. J Biol Chem 270:15923-15925.
17. Bauer F, Urdaci M, Aigle M, Crouzer M (1993): Alteration of a yeast SH3 protein leads to conditional viability with defects in cytoskeletal and budding patterns. Mol Cell Biol 13:5070-5084.
18. Beckmann H, Su LK, Kadesch T (1990): TFE3: A helix-loop-helix protein that activates transcription through the immunoglobulin enhancer μE3 motif. Genes Dev 4:167-179.
19. Beijersbergen RL, Hijmans EM, Zhu L, Bernards R (1994). Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation. EMBO J 13:4080-4086.
20. Bello-Fernandez C, Packham G, Cleveland JL (1993): The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci USA 90:7804-7808.
21. Benvenisty N, Leder A, Kuo A, Leder P (1992): An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence. Genes Dev 6: 2513-2523.
22. Ben-Yosef T, Yanuka O, Benvenisty N (1996): ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, GCN4, in yeast. Oncogene 13:1859-1866.
23. Berberich S, Hyde-DeRuyscher N, Espenshade P, Cole M (1992): max encodes a sequence-specific DNA-binding protein and is not regulated by serum growth factors. Oncogene 7:775-779.
24. Berberich SJ, Cole MD (1992): Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/ Max heterodimers. Genes Dev 6:166-176.
25. Bernards R, Dessain SK, Weinberg RA (1986): N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastoma. Cell 47:667-674.
26. 1 arrest through reduction of Cyclin E CDK2 kinase activity. Oncogene 15:1347-1356.
27. Bhatia K, Huppi, K, Spangler G, Siwarski D, Iyer R, Magrath I (1993): Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nature Gen 5:56-61.
28. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H (1990): Sequence-specific DNA binding by the c-Myc protein. Science 250:1149-1151.
29. Blackwell TK, Huang J, Ma A, Kretzner L, Alt FW, Eisenman RN, Weintraub H (1993): Binding of Myc proteins to canonical and noncanonical DNA sequences. Mol Cell Biol 13:5216-5224.
30. Blackwood EM, Eisenman RN (1991): Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251:1211-1217.
31. Blackwood EM, Lüscher B, Eisenman RN (1992): Myc and Max associate in vivo. Genes Dev 6:71-80.
32. Born TL, Frost JA, Schonthal A, Prendergast GC, Feramisco JR (1994): c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol 14:5710-5718.
33. Boyd KE, Farnham PJ (1997): Myc vs. USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol 17:2529-2537.
34. Brough DE, Hofmann TJ, Ellwood KB, Townley RA, Cole MD (1995) An essential domain of the c-Myc protein interacts with a nuclear factor that is also required for E1A-mediated transformation. Mol Cell Biol 15:1536-1544.
35. Bush SJ, Sassone-Corsi P (1990): Dimers, leucine zippers and DNA-binding domains. Trends Genet 6:36-40.
36. Carr CS, Sharp PA (1990): A helix-loop-helix protein related to the immunoglobulin E box-binding proteins. Mol Cell Biol 10:4384-4388.
37. Chen C, Nussenzweig A, Guo M, Kim D, Li GC, Ling CC (1996): Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis. Oncogene 13:1659-1665.
38. Chou TY, Dang CV, Hart GW (1995): Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci USA 92:4417-4421.
39. Cole MD (1986): The myc oncogene: its role in transformation and differentiation. Ann Rev Genet 20:361-384.
40. Coppola JA, Cole MD (1986): Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. Nature 320:760-763.
41. Courey AJ, Tjian R (1988): Analysis of Sp1 in vivo reveals multiple transcriptional domains, including a novel glutamine-rich activation motif. Cell 55:887-898.
42. Crouch DH, Lang C, Gillespie DA (1990): The leucine zipper domain of avian c-Myc is required for transformation and autoregulation. Oncogene 5:683-689.
43. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ (1994): Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9:3635-3645.
44. Dang CV, van Dam H, Buckmire M, Lee WMF (1989): DNA-binding domain of human c-Myc produced in Escherichia coll. Mol Cell Biol 9:2477-2486.
45. Davis AC, Wims M, Spotts GD, Hann SR, Bradley A (1993): A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev 7:671-682.
46. Davis LJ, Halazonetis TD (1993): Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max. Oncogene 8:125-132.
47. De Camilli P, Thomas A, Cofiell R, Folli F, Lichte B, Piccolo G, Meinck HM, Austoni M, Fassetta G, Bottazzo G (1993): The synaptic vesicle-associated protein amphiphysin is the 128-kDa autoantigen of stiff-man syndrome with breast cancer. J Exp Med 178:2219-2223.
48. Desbarats L, Gaubatz S, Eilers M (1996): Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev 10:447-460.
49. Domashenko AD, Latham KE, Hatton KS (1997): Expression of Myc-family, Myc-interacting, and Myc-target genes during preimplantaion mouse development. Mol Reprod Dev 47:57-65.
50. Dorsey MJ, Echlin DR, Utama FE, Ma J, Taparowsky EJ (1998): OS-9 interacts with Myc and inhibits transcription activation. In preparation.
51. Eilers M, Schirm S, Bishop JM (1991): The MYC protein activates transcription of the α-prothymosin gene. EMBO J 10:133-141.
52. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Water CM, Penn LZ, Hancock DC (1992): Induction of apoptosis in fibroblasts by c-Myc protein. Cell 69:119-128.
53. Facchini LM, Chen S, Marhin WW, Lear JN, Penn LZ (1997): The Myc negative autoregulation mechanism requires Myc-Max association and involves the c-myc P2 minimal promoter. Mol Cell Biol 17:100-114.
54. Freytag SO, Dang CV, Lee WMF (1990): Definition of the activities and properties of c-Myc required to inhibit cell differentiation. Cell Growth Diff 1:339-343.
55. Fukasawa K, Wiener F, Vande Woude GF, Mai S (1997): Genomic instability and apoptosis are frequent in p53 deficient young mice. Oncogene 15:1295-1302.
56. Gafori JJ, Perez M, Algarra I, Mialdea MJ, Ljunggren HG, Garrido F (1991): Differential mRNA levels of c-myc, c-fos and MHC class I in several clones of a murine fibrosarcoma. Int J Cancer 49:906-910.
57. Galaktionov K, Chen X, Beach D (1996): Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382: 511-517.
58. Gallant P, Shiio Y, Cheng PF, Parkhurst SM, Eisenman RN (1996): Myc and max homologs in Drosophila. Science 274:1523-1526.
59. Garmyn M, Yaar M, Holbrook N, Gilchrest BA (1991): Immediate and delayed molecular response of human keratinocytes to solar-simulated irradiation. Lab Invest 65:471-478.
60. Gaubatz S, Meichle A, Eilers M (1994): An E-box element localized in the first intron mediates regulation of the prothymosin α gene by c-myc. Mol Cell Biol 14:3853-3862.
61. Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R, Eilers M (1995): Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J 14:1508-1519.
62. Grandori C, Mac J, Siëbelt F, Ayer DE, Eisenman RN (1996): Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo. EMBO J 15:4344-4357.
63. Grandori C, Eisenman RN (1997): Myc target genes. Trends Biochem Sci 22:177-181.
64. Gregor PD, Sawadogo M, Roeder RG (1990): The adenovirus major late transcription factor USF is a member of the helix-loop-helix group of regulatory proteins and binds to DNA as a dimer. Genes Dev 4:1730-1740.
65. Griffioen M, Peltenburg LT, van Oorschot DA, Schrier PI (1995): C-Myc represses transiently transfected HLH class I promoter sequences not locus-specifically. Immunology 193:238-247.
66. Grignani F, Lombardi L, Inghirami G, Sternas L, Cechova K, Dalla-Favera R (1990): Negative autoregulation of c-myc gene expression is inactivated in transformed cells. EMBO J 9:3913-3922.
67. Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R (1994): Binding and suppression of the Myc transcription activation domain by p107. Science 264:251-254.
68. Gupta K, Anad G, Yin X, Grove L, Prochownik EV (1998): Mmip1 : a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc. Oncogene 16:1149-1159.
69. Gupta S, Seth A, Davis RJ (1993): Transactivation of gene expression by Myc is inhibited by mutation at the phosphorylation sites Thr-58 and Ser-62. Proc Natl Acad Sci USA 90:3216-3220.
70. Haas K, Johannes C, Geisen C, Schmidt T, Karsunky H, Blasskampmann S, Obe G, Moroy T (1997): Malignant transformation by Cyclin E and Ha-Ras correlates with lower sensitivity towards induction of cell death but requires functional Myc and CDK4. Oncogene 15:2615-2623.
71. Halazonetis TD, Kandil AN (1991): Determination of the c-Myc DNA binding site. Proc Natl Acad Sci USA 88:6162-6166.
72. Hann SR, Eisenman RN (1984): Proteins encoded by the human c-myc oncogene. Differential expression in neoplastic cells. Mol Cell Biol 4:2486-2497.
73. Hann SR, Thompson CB, Eisenman RN (1985): c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature 314:366-369.
74. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM (1994): Effects of c-myc expression on cell cycle progression. Mol Cell Biol 14:5748-5755.
75. Hateboer G, Timmers HTM, Rustgi AK, Billaud M, Van't Veer LJ, Bernards R (1993): TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein. Proc Natl Acad Sci USA 90:8489-8493.
76. Henriksson M, Bakardjiev A, Klein G, Lüscher B (1993): Phosphorylation sites mapping in the N-terminal domain of c-Myc modulate its transforming potential. Oncogene 8:3199-3209.
77. Henriksson M, Lüscher B (1996): Proteins of the Myc net-work: essential regulators of cell growth and differentiation. Advances Cancer Res 68:109-182.
78. Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV (1994): Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci USA 91:6875-6879.
79. Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, Raffeld M, Hann SR, Dang CV (1995): A link between increased transforming activity of lymphoma-derived myc mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol 15:4031-4042.
80. Hu YF, Lüscher B, Admon A, Mermod N, Tjian R (1990): Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity. Genes Dev 4:1741-1752.
81. Hurlin PJ, Ayer DE, Grandori C, Eisenman RN (1994): The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes. Cold Spring Harbor Symposia on Quantitative Biol, Cold Spring Harbor Laboratory Press, 59: 109-116.
82. Hurlin PJ, Quéva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN (1995): Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14:5646-5659.
83. Hurlin PJ, Quéva C, Eisenman RN (1997): Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev 11:44-58.
84. Inghirami G, Grignani F, Sternas L, Lombardi L, Knowles DM, Dalla-Favera R (1990): Down-regulation of LFA-1 adhesion receptors by c-myc oncogene in human B lymphoblastoid cells. Science 250:682-686.
85. Izawa M (1993): Molecular cloning and sequencing of rat Max cDNA: castration-induced expression of the 2 kb transcript in male accessory sex organs of rats. Biochimica et Biophysica Acta 1216:492-494.
86. Jansen-Dürr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M (1993): Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA 90:3685-3689.
87. Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L, Schmidt EV (1996): An essential E box in the promoter of of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-Myc. Mol Cell Biol 16:4754-4764.
88. Judware R, Culp LA (1995): Over-expression of transfected N-Myc in human SKNSH neuroblastoma cells down-regulates expression of β1 integrin subunit. Oncogene 11:2599-2607.
89. Judware R, Lechner R, Culp LA (1995): Inverse expression of the N-myc oncogene and β1 integrin in human neuroblastoma: relationships to disease progression in a nude mouse model. Clin Exp Metastasis 13:123-133.
90. Judware R, Culp LA (1997a): Concomitant down-regulation of expression of integrin subunits by N-Myc in human neuroblastoma cells: differential regulation of α2, α3, and β1. Oncogene 14:1341-1350.
91. Judware R, Culp LA (1997b): N-Myc overexpression down-regulates α3β1 integrin expression in human Saos-2 osteosarcoma cells. Clin Exp Metastasis 15:228-238.
92. Kaddurah-Daouk R, Greene JM, Baldwin AS Jr, Kingston RE (1987): Activation and repression of mammalian gene expression by the c-Myc protein. Genes Dev 1:347-357.
93. Kato GJ, Barrett J, Villa-Garcia M, Dang CV (1990): An amino-terminal c-Myc domain required for neoplastic transformation activates transcription. Mol Cell Biol 10:5914-5920.
94. Kato GJ, Lee WMF, Chen L, Dang CV (1992): Max: functional domains and interaction with c-Myc. Genes Dev 6:81-92.
95. Kelly K, Cochran BH, Stiles CD, Leder P (1983): Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 35:603-610.
96. King MW, Blackwood EM, Eisenman RN (1993): Expression of two distinct homologues of Xenopus Max during early development. Cell Growth Diff 4:85-92.
97. Kingston RE, Baldwin AS Jr, Sharp PA (1984): Regulation of heat shock protein 70 gene by expression of c-myc. Nature 312:280-282.
98. Kohl NE, Kanda N, Schreck RR, Bruns G, Latt SA, Gilbert F, Alt FW (1983): Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell 35:359-367.
99. Kretzner L, Blackwood EM, Eisenman RN (1992): Myc and Max possess distinct transcriptional activities. Nature 359:426-429.
100. Krylov D, Kasai K, Echlin DR, Taparowsky EJ, Arnheiter H, Vinson C (1997): A general method to design dominant negatives to B-HLHZip proteins that abolish DNA binding. Proc Natl Acad Sci USA 94:12274-12279.
101. Land H, Parada F, Weinberg RA (1983): Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602.
102. Landschulz WH, Johnson PF, McKnight SL (1988): The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240:1759-1764.
103. Larsson LG, Pettersson M, Öberg F, Nilsson K, Lüscher B (1994): Expression of mad, mxil, max, and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 9:1247-1252.
104. Lee LA, Dolde C, Barrett J, Wu CS, Dang CV (1996): A link between c-Myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest 97:1687-1695.
105. Lee LA, Dang CV (1997): C-myc transrepression and cell transformation. Curr Topics Micro Immun 224: 131-135.
106. Lee TC, Li L-H, Philipson L, Ziff EB (1997): Myc represses transcription of the growth arrest gene gasi. Proc Natl Acad Sci USA 94:12886-12891.
107. Lemaitre J-M, Buckle RS, Méchali M (1996): c-Myc in the control of cell proliferation and embryonic development. Adv Cancer Res 70:95-144.
108. Lenardo M, Rustgi AK, Schievella AR, Bernards R (1989): Suppression of MHC class I gene expression by N-myc through enhancer inactivation. EMBO J 8:3351-3355.
109. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR (1997): Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 387:422-426.
110. Lewis BC, Shim H, Li Q, Wu CS, Lee LA, Maity A, Dang CV (1997): Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol 17:4967-4978.
111. Li L-H, Nerlov C, Prendergast G, MacGregor D, Ziff EB (1994): c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J 13:4070-4079.
112. Lucke-Huhle C, Mai S, Moll J (1997): c-Myc overexpression facilitates radiation-induced DHFR gene amplification. Int J Rad Bio 71:167-175.
113. Lüscher B, Kuenzel EA, Krebs EG, Eisenman RN (1989): Myc oncoproteins are phosphorylated by casein kinase II. EMBO J 8:1111-1119.
114. Lutterbach B, Hann SR (1994): Hierarchial phosphorylation at N-terminal transformation sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol 14:5510-5522.
115. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M (1996): Conditional expression of N-Myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13:803-812.
116. Maheswaran S, Lee H, Sonenshein GE (1994): Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein. Mol Cell Biol 14:1147-1152.
117. Mai S (1994): Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. Gene 148:253-260.
118. Mai S, Jalava A (1994): C-Myc binds to the 5′ flanking sequence motifs of the dihydrofolate reductase gene in cellular extracts role in proliferation. Nucleic Acids Res 22:2264-2273.
119. Mai S, Mårtensson IL (1995): The c-Myc protein represses the λ5 and TdT initiators. Nucleic Acids Res 23:1-9.
120. Mai S, Hanley-Hyde J, Fluri M (1996): c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene 12:277-288.
121. Mäkelä TP, Koskinen PJ, Västrik I, Alitalio K (1992): Altenative forms of Max as enhancers or suppressors of Myc-Ras cotransformation. Science 256:373-377.
122. Marhin WW, Hei YJ, Chen S, Jiang Z, Gallie BL, Phillips RA, Penn LZ (1996): Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation. Oncogene 12:43-52.
123. Marhin WW, Chen S, Facchini LM, Fornace AJ, Penn LZ (1997): Myc represses the growth arrest gene gadd45. Oncogene 14:2825-2834.
124. Manabe A, Iguchi-Ariga SM, Iizuka H, Ariga H (1996): Transcriptional repression activity of N-Myc protein requires phosphorylation by MAP kinase. Biochem Biophys Res Comm 219:813-823.
125. McEwan IJ, Dahlman-Wright K, Ford J, Wright APH (1996): Functional interaction of the c-Myc transactivation domain with the TATA binding protein: Evidence for an induced fit model of transactivation domain folding. Biochemistry 35:9584-9593.
126. McMahon S, Van Buskirk HA, Dugan KA, Copeland TD, Cole MD (1998): The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell, in press.
127. Meichle A, Philipp A, Eilers M (1992): The functions of Myc proteins. Biochimica et Biophysica Acta 1114: 129-146.
128. Meroni G, Reymond A, Alcalay M, Borsani G, Tanigami A, Tonlorenzi R, Nigro CL, Messali S, Zollo M, Ledbetter DH, Brent R, Ballabio A, Carrozzo R (1997): Rox, a novel bHLHZip protein expressed in quiescent cells that heterodomierizes with Max, binds a noncanonical E box and acts as a transcriptional repressor. EMBO J 16:2892-2906.
129. 1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 15:2527-2535.
130. Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Kusumoto H, Haraguchi M, Ueo H, Akiyoshi T (1997): Analysis of ornithine decarboxylase messenger ribonucleic acid expression in colorectal carcinoma. Diseases of the Colon & Rectum 40:1095-1100.
131. Mimori K, Mori M, Shiraishi T, Tanaka S, Haraguchi M, Ueo H, Shirasaka C, Akiyoshi T (1998): Expression of ornithine decarboxylase mRNA and c-Myc mRNA in breast tumors. Int J Oncol 12:597-601.
132. Min S, Taparowsky EJ (1992): v-Myc, but not Max, possesses domains that function in both transcription activation and cellular transformation. Oncogene 7: 1531-1540.
133. Min S, Mascarenhas NT, Taparowsky EJ (1993): Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation. Oncogene 8:2691-2701.
134. Miner JH, Wold BJ (1991): c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol Cell Biol 11:2842-2851.
135. Mol PC, Wang R-H, Batey DW, Lee LA, Dang CV, Berger SL (1995): Do products of the myc protooncogene play a role in transcriptional regulation of the prothymosin α gene? Mol Cell Biol 15:6999-7009.
136. Moll J, Schmid P, Sansig G, van der Putten H (1996): The pattern of prothymosin α gene expression coincides with that of myc protooncogenes during mouse embryogenesis. Histochemical J 28:45-52.
137. Mori M, Barnard GF, Staniunas RJ, Jessup JM, Steele GD Jr, Chen LB (1993): Prothymosin-α mRNA expression correlates with that of c-Myc in human colon cancer. Oncogene 8:2821-2826.
138. Murre C, McCaw PS, Baltimore D (1989a): A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 56:777-783.
139. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, Buskin JN, Hauschka, Lassar AB, Weintraub H, Baltimore D (1989b): Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58:537-544.
140. Murre C, Bain G, van Dijk MA, Engel I, Furnari BA, Massari ME, Matthews JR, Quong MW, Rivera RR, Stuiver MH (1994): Structure and function of helix-loop-helix proteins. Biochimica et Biophysica Acta 1218:129-135.
141. Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride OW, Bertness V, Hollis GF, Minna JD (1985): L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature 318:69-73.
142. Nishikura K, Murray JM (1988): The mechanism of inactivation of the normal c-myc gene locus in human Burkitt lymphoma cells. Oncogene 2:493-498.
143. Novina CD, Roy AL (1996): Core promoters and transcriptional control. Trends Genet 12:351-355.
144. Onclercq R, Gilardi P, Lavenu A, Cremisi C (1988): c-myc products trans-activate the adenovirus E4 promoter in EC stem cells by using the same target sequence as E1A products. J Virol 62:4533-4537.
145. Packham G, Cleveland JL (1994): Ornithine decarboxylase is a mediator of c-Myc induced apoptosis. Mol Cell Biol 14:5741-5747.
146. Packham G, Cleveland JL (1995): c-Myc and apoptosis. Biochimica et Biophysica Acta 1242:11-28.
147. Packham G, Cleveland JL (1997): Induction of ornithine decarboxylase by IL-3 is mediated by sequential c-Myc-independent and c-Myc-dependent pathways. Oncogene 15:1219-1232.
148. Pazin MJ, Kadonaga JT (1997): What's up and down with histone deacetylation and transcription? Cell 89:325-328.
149. Peltenburg LT, Dee R, Schrier PI (1993): Down-regulation of HLA class I expression by c-Myc in human melanoma is independent of enhancer A. Nucl Acids Res 21:1179-1185.
150. Peña A, Reddy CD, Wu S, Hickok NJ, Reddy EP, Yumet G, Soprano DR, Soprano KJ (1993): Regulation of human ornithine decarboxylase expression by the c-Myc/Max protein complex. J Biol Chem 268:27277-27285.
151. Peña A, Wu S, Hickok NJ, Soprano DR, Soprano KJ (1995): Regulation of human ornithine decarboxylase expression following prolonged quiescence: role for the c-Myc/Max protein complex. J Cell Phys 162:234-245.
152. Penn LJZ, Brooks MW, Laufer EM, Land H (1990a): Negative autoregulation of c-myc transcription. EMBO J 9:1113-1121.
153. Penn LJZ, Brooks MW, Laufer EM, Littlewood TD, Morgenstern JP, Evan GI, Lee WM, Land H (1990b): Domains of human c-Myc protein required for autosuppression and cooperation with ras oncogenes are overlapping. Mol Cell Biol 10:4961-4966.
154. Perez-Roger I, Solomon DLC, Sewing A, Land H (1997): Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27Kip1 binding to newly formed complexes. Oncogene 14:2373-2381.
155. Peters MA, Sollenberger KS, Kao TL, Taparowsky EJ (1997): A minimal regulatory region maintains constitutive expression of the max gene. Mol Cell Biol 17:1037-1048.
156. Peukert K, Staller P, Schneider A, Carmichael G, Hänel F, Eilers M (1997): An alternative pathway for gene regulation by Myc. EMBO J 16:5672-5686.
157. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M (1994): Repression of Cyclin Dl: a novel function of Myc. Mol Cell Biol 14:4032-4043.
158. Prasad VS, Lafond RE, Zhou M, Jacobsen KA, Osmond DG, Sidman CL (1997): Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of E-mμ-Myc transgenic mice by deregulated c-myc transgene. Mol Carcinogen 18:66-77.
159. Prendergast GC, Diamond LE, Dahl D, Cole MD (1990): The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1. Mol Cell Biol 10:1265-1269.
160. Prendergast GC, Lawe D, Ziff EB (1991): Association of Myn, the murine homolog of Max, with c-Myc stimulates methylation-sensitive DNA binding and Ras cotransformation. Cell 65:395-407.
161. Prendergast GC, Ziff EB (1992): A new bind for Myc. Trends Genet 8:91-96.
162. Prochownik EV, VanAntwerp ME (1993): Differential patterns of DNA binding by Myc and Max proteins. Proc Natl Acad Sci USA 90:960-964.
163. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR (1994): Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 9:59-70.
164. Pusch O, Soucek T, Hengstschläger-Ottnad E, Bernaschek G, Hengstschläger M (1997): Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase. DNA Cell Biol 16:737-747.
165. Quéva C, Hurlin PJ, Foley KP, Eisenman RN (1998): Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene 16:967-977.
166. Raschella G, Romeo A, Negroni A, Pucci S, Dominici C, Castello MA, Bevilacqua P, Felsani A, Calabretta B (1994) Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation. Cancer Res 54:2251-2255.
167. Reddy CD, Dasgupta P, Saikumar P, Dudek H, Rauscher FJ III, Reddy EP (1992): Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation. Oncogene 7:2085-2092.
168. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V (1993): c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Diff 4:57-65.
169. Resar LMS, Dolde C, Barrett JF, Dang CV (1993): B-Myc inhibits neoplastic transformation and transcriptional activation by c-Myc. Mol Cell Biol 13:1130-1136.
170. Rosenwald IB, Rhoads DB, Callana LD, Isselbacher KJ, Schmidt EV (1993): Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-Myc. Proc Natl Acad Sci USA 90:6175-6178.
171. Rosenwald IB (1996): Upregulated expression of the genes encoding translation initiation factsors eIF-4E and eIF-2α in transformed cells. Cancer Lett 102:113-123.
172. Roy AL, Meisterernst M, Pognonec P, Roeder RG (1991): Cooperative interaction of an initiator-binding transcription initiation factor and the helix-loop-helix activator USF. Nature 354:245-248.
173. Roy AL, Carruthers C, Gutjahr T, Roeder RG (1993): Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 365:359-361.
174. Roy B, Beamon J, Balint E, Reisman D (1994): Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 14:7805-7815.
175. Rustgi AK, Dyson N, Bernards R (1991): Amino-terminal domains of c-myc and N-myc proteins mediate binding to the retinoblastoma gene product. Nature 352:541-544.
176. Sadowski I, Ma J, Triezenberg S, Ptashne M (1988): GAL4-VP16 is an unusually potent transcriptional activator. Nature 335:563-564.
177. Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC (1996): BIN1 is a novel Myc-interacting protein with features of a tumor suppressor. Nature Genet 14:69-77.
178. Schreiber-Agus N, Horner J, Torres R, Chiu FC, DePinho RA (1993): Zebra fish myc family and max genes: Differential expression and oncogenic activity throughout vertebrate evolution. Mol Cell Bio 13:2765-2775.
179. Schreiber-Agus N, Chin L, Chen K, Torres R, Thomson CT, Sacchettini JC, DePinho RA (1994): Evolutionary relationships and functional conservation among vertebrate Max-associated proteins: the zebra fish homolog of Mxil. Oncogene 9:3167-3177.
180. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA (1995): An amino-terminal domain of Mxil mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786.
181. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J (1983): Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 305:245-248.
182. Seliger B, Pfizenmaier K (1989): Post-transcriptional downregulation of MHC class I expression in oncogenetransformed cells is reverted by IFN-γ and TNF-α. J Immunogenetics 16:315-320.
183. 2-terminal domain of c-Myc increases transactivation of gene expression. J Biol Chem 266:23521-23524.
184. 1 transition in nontransformed cells. Cell Growth Diff 4:93-104.
185. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, Dalla-Favera R, Dang CV (1997): c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663.
186. Shim H, Chun YS, Lewis BC, Dang CV (1998): A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Nat Acad Sci USA 95:1511-1516.
187. Shrivastava A, Saleque S, Kalpana GV, Artandi S, Goff SP, Calame K (1993): Inhibition of transcriptional regulator Yin-Yang-1 by association with c-Myc. Science 262:1889-1892.
188. Shrivastava A, Calame K (1994): An analysis of genes regulated by the multi-functional transcriptional regulator Yin-Yang-1. Nucl Acids Res 22:5151-5155.
189. Sivak LE, Tai KF, Smith RS, Dillon PA, Brodeur GM, Carroll WL (1997): Autoregulation of human N-myc oncogene is disrupted in amplified but not single-copy neuroblastoma cell lines. Oncogene 15:1937-1946.
190. Solomon DL, Phillipp A, Eilers M (1995): Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Oncogene 11:1893-1897.
191. Spencer CA, Groudine M (1991): Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56:1-48.
192. Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF (1992): Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev 6:2235-2247.
193. Stringer KF, Ingles CJ, Greenblatt J (1990): Direct and selective binding of an acidic transcritpional activation domain to the TATA-box factor TFIID. Nature 345:783-786.
194. Su YA, Hutter CM, Trent JM, Meltzer PS (1996): Complete sequence analysis of a gene (OS-9) ubiquitously expressed in human tissues and amplified in sarcomas. Mol Carcin 15:270-275.
195. Suen TC, Hung MC (1991): c-Myc reverses Neu-induced transformed morphology by transcriptional repression. Mol Cell Biol 11:354-362.
196. Sugio K, Nakagawara A, Sasazuki T (1991): Association of expression between N-myc gene and major histocompatibility complex class I gene in surgically resected human neuroblastoma. Cancer 67:1384-1388.
197. Taparowsky EJ, Heaney ML, Parsons JT (1987): Oncogene-mediated multistep transformation of C3H10T1/2 cells. Cancer Res 47:4125-429.
198. 1 serum response genes and identification of a subset regulated by conditional Myc expression. Mol Biol Cell 5:375-388.
199. Taylor C, Jalava A, Mai S (1997): c-Myc dependent initiation of genomic instability during neoplastic transformation. Curr Topics Micro Immun 224:201-207.
200. Thompson CB, Challoner PB, Neiman PE, Groudine M (1985): Levels of c-myc oncogene mRNA are invariant throughout the cell cycle. Nature 314:363-366.
201. Tikhonenko AT, Hartman AR, Linial ML (1993): Overproduction of v-Myc in the nucleus and its excess over Max are not required for avian fibroblast transformation. Mol Cell Biol 13:3623-3631.
202. Tikhonenko AT, Black DJ, Linial ML (1996): Viral Myc oncoproteins in infected fibroblasts down-modulate thrombospondin-1, a possible tumor suppressor gene. J Biol Chem 271:30741-30747.
203. Tsuneoka M, Nakano F, Ohgusu H, Mekada E (1997): c-myc activates RCC1 gene expression through E-box elements. Oncogene 14:2301-2311.
204. van't Veer LJ, Beijersbergen RL, Bernards R (1993): N-Myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-κ B. EMBO J 12:195-200.
205. Vareli K, Frangou-Lazaridis M, Tsolas O (1995): Prothymosin α mRNA levels vary with c-myc expression during tissue proliferation, viral infection and heat shock. FEBS Lett 371:337-340.
206. Vennstrom B, Sheiness D, Zabielski J, Bishop JM (1982): Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 42:773-779.
207. Verrijzer CP, Tjian R (1996): TAFs mediate transcriptional activation and promoter selectivity. Trends Biochem Sci 21:338-342.
208. Versteeg R, Noordermeer IA, Krüse-Wolters M, Ruiter DJ, Schrier PI (1988): c-myc down-regulates class I HLA expression in human melanomas. EMBO J 7: 1023-1029.
209. Wagner AJ, Meyers C, Laimins LA, Hay N (1993): c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Diff 4:879-883.
210. Walhout AJM, Gubbels JM, Bernards R, Vandervliet PC, Timmers HTM (1997): c-Myc/Max heterodimers bind cooperatively to the E-box sequences in the first intron of the rat ornithine decarboxylase (ODC) gene. Nucleic Acids Res 25:1493-1501.
211. Wang S, Bartolome JV, Schanberg SM (1996): Neonatal deprivation of maternal touch may suppress ornithine decarboxylase via down-regualtion of the protooncogenes c-myc and max. J Neurosci 16:836-842.
212. Wang X, Peters MA, Utama FE, Wang Y, Taparowsky EJ (1998): The adrenomedullin gene is a target for negative regulation by the myc transcription complex. Submitted for publication.
213. Waters CM, Littlewood TD, Hancock DC, Moore JP, Evan GI (1991): c-myc protein expression in untransformed fibroblasts. Oncogene 6:797-805.
214. Watt RA, Shatzman AR, Rosenberg M (1985): Expression and characterization of the human c-myc DNA-binding protein. Mol Cell Biol 5:448-456.
215. Weihua X, Lindner DJ, Kalvakolanu DV (1997): The interferon-inducible murine p48 (ISGF3γ) gene is regulated by protooncogene c-myc. Proc Natl Acad Sci USA 94: 7227-7232.
216. Weinberg RA (1989): Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721.
217. Wenzel A, Schwab M (1995): The mycN/max protein complex in neuroblastoma. Short review. Eur J Cancer 31A: 516-519.
218. Wu CG, Boers W, Reitsma PR, Vandeventer SJH, Chamuleau RAFM (1997): Overexpression of prothymosin α, concomitant with c-Myc, during rat hepatic carcinogenesis. Biochem Biophys Res Comm 232:817-821.
219. Wu S, Peña A, Korcz A, Soprano DR, Soprano KJ (1996): Overexpression of Mxil inhibits the induction of human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene 12:621-629.
220. Yaar M, Gilani A, DiBenedetto PJ, Harkness DD, Gilchrest BA (1993): Gene modulation accompanying differentiation of normal versus malignant keratinocytes. Exp Cell Res 206:235-243.
221. Yang BS, Geddes TJ, Pogulis RJ, DeCrombrugghe B, Freytag SO (1991): Transcriptional suppression of cellular gene expression by c-Myc. Mol Cell Biol 11:2291-2295.
222. Yang BS, Gilbert JD, Freytag SO (1993): Overexpression of Myc suppresses CCAAT transcription factor/nuclear factor 1-dependent promoters in vivo. Mol Cell Biol 13:3093-3102.
223. Yin X, Grove L, Prochownik EV (1998): Lack of transcriptional repression by max homodimers. Oncogene 16:2629-2637.
224. Zervos AS, Gyuris J, Brent R (1993): Mxil, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223-232.
225. Zhang H, Fan S, Prochownik EV (1997): Distinct roles for MAX protein isoforms in proliferation and apoptosis. J Biol Chem 272:17416-17424.